Skip to main content
TipRanks
Go Ultimate75% OFF

Zevra Therapeutics (ZVRA) Stock Statistics & Valuation Metrics

1,160 Followers

Total Valuation

Zevra Therapeutics has a market cap or net worth of $550.42M. The enterprise value is $482.86M.

Market Cap
$550.42M
Enterprise Value
$482.86M

Share Statistics

Zevra Therapeutics has 59,504,620 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
59,504,620
Owned by Insiders
1.46%
Owned by Institutions
66.25%

Financial Efficiency

Zevra Therapeutics’s return on equity (ROE) is 0.54 and return on invested capital (ROIC) is -1.65%.

Return on Equity (ROE)
0.54
Return on Assets (ROA)
0.29
Return on Invested Capital (ROIC)
-1.65%
Return on Capital Employed (ROCE)
-0.02
Revenue Per Employee
1.75M
Profits Per Employee
1.36M
Employee Count
61
Asset Turnover
0.37
Inventory Turnover
9.47

Valuation Ratios

The current PE Ratio of Zevra Therapeutics is 7.24. Zevra Therapeutics’s PEG ratio is 0.07.

PE Ratio
7.24
PS Ratio
3.73
PB Ratio
2.31
Price to FCF
14.41
Price to Operating Cash Flow
14.22
PEG Ratio
0.07

Income Statement

In the last 12 months, Zevra Therapeutics had revenue of 106.47M and earned 83.23M in profits. Earnings per share was 1.40.

Revenue
106.47M
Gross Profit
89.99M
Operating Income
-4.23M
Pretax Income
86.68M
Net Income
83.23M
EBITDA
98.71M
Earnings Per Share (EPS)
1.40

Cash Flow

In the last 12 months, operating cash flow was 38.74M and capital expenditures -459,000, giving a free cash flow of 38.28M billion.

Operating Cash Flow
38.74M
Free Cash Flow
38.28M
Free Cash Flow per Share
0.64

Dividends & Yields

Zevra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
6.84%
Earnings Yield
13.97%

Stock Price Statistics

Beta
0.78
52-Week Price Change
2.40%
50-Day Moving Average
10.99
200-Day Moving Average
10.89
Relative Strength Index (RSI)
38.37
Average Volume (3m)
956.75K

Important Dates

Zevra Therapeutics upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 03, 2026
Next Earnings Date
Mar 10, 2027
Ex-Dividend Date
―

Financial Position

Zevra Therapeutics as a current ratio of 5.68, with Debt / Equity ratio of 40.87%

Current Ratio
5.68
Quick Ratio
5.63
Debt to Market Cap
0.12
Net Debt to EBITDA
0.01
Interest Coverage Ratio
-0.53

Taxes

In the past 12 months, Zevra Therapeutics has paid 3.45M in taxes.

Income Tax
3.45M
Effective Tax Rate
0.04

Enterprise Valuation

Zevra Therapeutics EV to EBITDA ratio is 4.78, with an EV/FCF ratio of 11.45.

EV to Sales
2.97
EV to EBITDA
4.78
EV to Free Cash Flow
11.45
EV to Operating Cash Flow
11.32

Balance Sheet

Zevra Therapeutics has $195.57M in cash and marketable securities with $1.23M in debt, giving a net cash position of $194.34M billion.

Cash & Marketable Securities
$195.57M
Total Debt
$1.23M
Net Cash
$194.34M
Net Cash Per Share
$3.27
Tangible Book Value Per Share
$3.85

Margins

Gross margin is 95.19%, with operating margin of 31.47%, and net profit margin of 52.80%.

Gross Margin
95.19%
Operating Margin
31.47%
Pretax Margin
60.90%
Net Profit Margin
52.80%
EBITDA Margin
62.01%
EBIT Margin
61.06%

Analyst Forecast

The average price target for Zevra Therapeutics is $24.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$24.67
Price Target Upside
162.41% Upside
Analyst Consensus
Strong Buy
Analyst Count
7
Revenue Growth Forecast
75.10%
EPS Growth Forecast
103.22%

Scores

Smart Score
9
AI Score
73